Translating basic mechanisms of IgG effector activity into next generation cancer therapies

Cancer Immunity

Volumn 12, Issue , 2012, Pages

  Nimmerjahn, Falk ^a   Ravetch, Jeffrey V ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Antibody; Cancer therapy; Fc engineering; Fc receptor; Inflammation

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BLINATUMOMAB; CATUMAXOMAB; CD20 ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FC RECEPTOR IIA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; OFATUMUMAB; RITUXIMAB; TRASTUZUMAB; BISPECIFIC ANTIBODY;

ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL DEATH; DENDRITIC CELL; DRUG HALF LIFE; EFFECTOR CELL; FOLLICULAR LYMPHOMA; GENE MUTATION; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR IMMUNITY; UBIQUITINATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIBODIES, BISPECIFIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, FC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84862245287     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspec-tives. Haematologica 2010; 95: 135-143. (PMID: 19773256)
2. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007; 19: 239-245. (PMID: 17291742)
3. Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp Cell Res 2011; 317: 1278-1285. (PMID: 21459085)
4. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011; 25: 13-25. (PMID: 21090841)
5. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7: 1401-1413. (PMID: 17727329)
6. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 1073-1078. (PMID: 16151394)
7. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immu-nol 2006; 6: 343-357. (PMID: 16622479)
8. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG, Munoz-O'Regan D, O'Donnell SL, Lapachet ESG, Bengoechea T, Fishwild DM, Carmack CE, Kay RM, Huszar D. Antigen-specific human antibodies from mice comprising four distinct genetic mod-ifications. Nature 1994; 368: 856-859. (PMID: 8159246)
9. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9: 767-774. (PMID: 20811384)
10. Corti D, Sallusto F, Lanzavecchia A. High throughput cellular screens to interrogate the human T and B cell repertoires. Curr Opin Immunol 2011; 23: 430-435. (PMID: 21600751)
11. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 2002; 14: 798-802. (PMID: 12413532)
12. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103: 4005-4010. (PMID: 16537476)
13. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002; 2: 580-592. (PMID: 12154377)
14. Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik MJ, Cragg MS, Glennie MJ. Type II (tositu-momab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of comple-ment activation. Blood 2008; 112: 4170-4177. (PMID: 18583569)
15. Biburger M, Aschermann S, Schwab I, Lux A, Albert H, Danzer H, Woigk M, Dudziak D, Nimmerjahn F. Monocyte subsets responsi-ble for immunoglobulin G-dependent effector functions in vivo. Immunity 2011; 35: 932-944. (PMID: 22169040)
16. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc recep-tors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-446. (PMID: 10742152)
17. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Anti-body isotype-specific engagement of Fc gamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006; 203: 743-753. (PMID: 16520392)
18. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310: 1510-1512. (PMID: 16322460)
19. Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RH, van de Winkel JG, van Egmond M. Experimental anti-body therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol 2008; 181: 6829-6836. (PMID: 18981101)
20. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199: 1659-1669. (PMID: 15210744)
21. Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, St. John W, Weiner GJ. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009; 114: 5322-5330. (PMID: 19805620)
22. Wang SY, Weiner G. Complement and cellular cytotoxicity in anti-body therapy of cancer. Expert Opin Biol Ther 2008; 8: 759-768. (PMID: 18476787)
23. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of comple-ment. Blood 2008; 111: 1456-1463. (PMID: 18024795)
24. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008; 14: 6697-6703. (PMID: 18927313)
25. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colom-bat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgam-maRIIIa gene. Blood 2002; 99: 754-758. (PMID: 11806974)
26. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardiz-zoni A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796. (PMID: 18347005)
27. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is corre-lated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22: 4717-4724. (PMID: 15483014)
28. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947. (PMID: 12975461)
29. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sab-ourin JC, Boissière-Michot F. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clini-cal outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129. (PMID: 19164213)
30. Weng WK, Levy R. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma 2009; 50: 723-727. (PMID: 19452316)
31. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19-28. (PMID: 16413920)
32. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 poly-morphism. Blood 2011; 118: 3347-3349. (PMID: 21768303)
33. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leu-kemia: a phase 1-2 study. Blood 2008; 111: 1094-1100. (PMID: 18003886)
34. Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inade-quate response to methotrexate: a randomised, double-blind, pla-cebo-controlled clinical trial. Ann Rheum Dis 2011; 70: 2119-2125. (PMID: 21859685)
35. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276: 6591-6604. (PMID: 11096108)
36. Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Mokore PA, Johnson S, Bonvini E. Anti-tumor activity and toxico-kinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res 2011; 13: R123. (PMID: 22129105)
37. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activat-ing Fcgamma receptors. Cancer Res 2007; 67: 8882-8890. (PMID: 17875730)
38. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Rich-ards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68: 8049-8057. (PMID: 18829563)
39. Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009; 113: 3735-3743. (PMID: 19109559)
40. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000; 18: 739-766. (PMID: 10837074)
41. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725. (PMID: 17703228)
42. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28: 157-159. (PMID: 20081867)
43. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A 2008; 105: 20167-20172. (PMID: 19074274)
44. Potgieter TI, Cukan M, Drummond JE, Houston-Cummings NR, Jiang Y, Li F, Lynaugh H, Mallem M, McKelvey TW, Mitchell T, Nylen A, Rittenhour A, Stadheim TA, Zha D, d'Anjou M. Produc-tion of monoclonal antibodies by glycoengineered Pichia pastoris. J Biotechnol 2009; 139: 318-325. (PMID: 19162096)
45. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25: 21-50. (PMID: 17029568)
46. Lux A, Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv Exp Med Biol 2011; 780: 113-124. (PMID: 21842369)
47. Schwab I, Biburger M, Kronke G, Schett G, Nimmerjahn F. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 2012; epub ahead of print. (PMID: 22278120)
48. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475: 110-113. (PMID: 21685887)
49. Anthony RM, Nimmerjahn F. The role of differential IgG glycosyl-ation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant 2010; epub ahead of print. (PMID: 21150612)
50. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373-376. (PMID: 18420934)
51. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identifica-tion of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008; 105: 19571-19578. (PMID: 19036920)
52. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-673. (PMID: 16888140)
53. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44: 1524-1534. (PMID: 17045339)
54. Ferrara C, Stuart F, Sondermann P, Brunker P, Umaña P. The car-bohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281: 5032-5036. (PMID: 16330541)
55. Ferrara C, Grau S, Jäger C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umaña P, Benz J. Unique carbohydrate-carbohydrate interactions are required for high affin-ity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108: 12669-12674. (PMID: 21768335)
56. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sonder-mann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotox-icity. Blood 2010; 115: 4393-4402. (PMID: 20194898)
57. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umaña P, Manenti L, Tabernero J. Phase I pharmaco-kinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011; 29: 3783-3790. (PMID: 21900113)
58. Peipp M, van de Winkel JG, Valerius T. Molecular engineering to improve antibodies' anti-lymphoma activity. Best Pract Res Clin Haematol 2011; 24: 217-229. (PMID: 21658620)
59. Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leu-kemic cells. J Immunother 2008; 31: 871-884. (PMID: 18833000)
60. Ardnt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 1999; 94: 2562-2568. (PMID: 10515858)
61. Kipriyanov SM, Little M. Generation of recombinant antibodies. Mol Biotechnol 1999; 12: 173-201. (PMID: 10596374)
62. Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, Fey GH. Heterodi-meric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett 2011; 303: 128-139. (PMID: 21339041)
63. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22-30. (PMID: 19169956)
64. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36: 458-467. (PMID: 20347527)
65. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Rein-hardt C, Baeuerle PA, Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977. (PMID: 18703743)
66. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpf-heller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, Steinman RM, Nussenzweig MC. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315: 107-111. (PMID: 17204652)
67. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state condi-tions in vivo. J Exp Med 2001; 194: 769-779. (PMID: 11560993)
68. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, Iyoda T, Ravetch J, Dhodapkar M, Inaba K, Nussenzweig M. Den-dritic cell function in vivo during the steady state: a role in periph-eral tolerance. Ann N Y Acad Sci 2003; 987: 15-25. (PMID: 12727620)
69. Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 2011; 333: 1030-1034. (PMID: 21852502)
70. White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 2011; 187: 1754-1763. (PMID: 21742972)
71. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A. An Fcgamma receptor-dependent mechanism drives antibody-medi-ated target-receptor signaling in cancer cells. Cancer Cell 2011; 19: 101-113. (PMID: 21251615)
72. Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, Koopman WJ, Kimberly RP. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 2003; 171: 562-568. (PMID: 12847219)
73. Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE. Anti-body-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythe-matosus. J Immunol 2011; 186: 4223-4233. (PMID: 21357255)
74. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg MS. Antigenic modu-lation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115: 5191-5201. (PMID: 20223920)
75. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg MS, Glennie MJ. Fc gamma receptor IIb on target B cells promotes rituximab internal-ization and reduces clinical efficacy. Blood 2011; 118: 2530-2540. (PMID: 21768293)